De Nardo G L, Kroger L A, Mirick G R, Lamborn K R, De Nardo S J
University of California Davis Medical Center, Sacramento, USA.
Int J Biol Markers. 1995 Apr-Jun;10(2):67-74. doi: 10.1177/172460089501000201.
Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy. However, radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing "HAMA" activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabeled Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Medial survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).
据报道，宿主针对所给予的抗体产生人抗鼠抗体（HAMA）是抗体成像和治疗中的一个问题。然而，放射免疫疗法已被证明对B细胞恶性肿瘤患者有效，因为他们的免疫缺陷状态可预防或延迟对鼠抗体产生HAMA反应。对60例B淋巴细胞性非霍奇金淋巴瘤或慢性淋巴细胞白血病患者检测了基线HAMA活性，并对随后接受放射性标记Lym-1抗体治疗的43例患者进行了连续检测。在筛选考虑治疗的60例患者中，有3例（5%）存在预先存在的“HAMA”活性。在接受多剂量放射性标记Lym-1抗体治疗的43例患者中，HAMA产生的发生率为12例（28%）。在HAMA阳性患者中没有类过敏反应或相关反应的证据。HAMA活性在14%的患者（43例中的6例）中中断了治疗，但并未排除对放射性标记Lym-1治疗的治疗反应。HAMA阳性患者的中位生存期（18个月）比未产生HAMA活性的患者（9个月）更长。
